FEBUXOSTAT: A NEW AGENT FOR LOWERING SERUM URATE
FEBUXOSTAT: A NEW AGENT FOR LOWERING SERUM URATE
复制标题
DOI：
10.1358/dot.2009.045.004.1354217
复制
发表时间：
2009-04-01
期刊：
影响因子：
1.8
通讯作者：
Pilinger, Michael H.
中科院分区：
文献类型：
--
作者：
Keenan, Robert T.;Pilinger, Michael H.
痛风的患病率在过去几十年中一直在增加流行病的比例。高尿酸血症已被证明与代谢综合征有关，是心血管疾病的独立危险因素。近年来，高尿酸血症、肥胖和衰老之间的关联为开发治疗高尿酸血症和痛风的替代方法提供了动力。非布司他是一种新的非嘌呤黄嘌呤氧化酶抑制剂，适用于慢性痛风。非布司他已被证明可以快速有效地降低慢性痛风患者的血清尿酸盐水平。本文将综述非布司他、其药代动力学和药效学、疗效和不良事件以及在合并症患者中的应用。该审查还将总结导致该药物在2008年获得欧盟委员会和2009年获得美国FDA批准的III期试验。可能的影响，药物可能在未来对痛风和高尿酸血症也将进行讨论。
The prevalence of gout has been increasing in epidemic proportions over the last several decades. Hyperuricemia has been shown to be associated with metabolic syndrome and to be an independent risk factor for cardiovascular disease. Associations between hyperuricemia, obesity and aging have provided an impetus in recent years to develop alternative methods of treating hyperuricemia and gout. Febuxostat is a new non-purine xanthine oxidase inhibitor indicated for chronic gout. Febuxostat has been shown to quickly and effectively lower serum urate levels in patients with chronic gout. This manuscript will review febuxostat, its pharmacokinetics and pharmacodynamics, efficacy and adverse events and use in patients with comorbid conditions. The review will also summarize the phase Ill trials leading up to the drug's approval by both the European Commission in 2008 and the U.S. FDA in 2009. Possible implications the medication may have in the future on gout and hyperuricemia will also be discussed.